Your CDMO
Pharmaceutical Partner

A Sterling Heritage

Sterling has over 50 year’s experience providing services to pharmaceutical and biotech companies. We specialise in complexity and technical innovation; our core services include high potency APIs, hazardous chemistry, controlled substances and peptides, as well as flow chemistry and biocatalysis.

API Development
and Manufacturing

At Sterling we provide comprehensive services throughout the lifecycle of your molecule, from route scouting and design to process optimisation, and clinical supply to commercial cGMP manufacturing.

ADC Development
and Manufacturing

Drawing upon years of experience working with ADCs from their earliest inception, our dedicated bioconjugation team is committed to supporting your project from discovery and development to preclinical and clinical cGMP manufacture.

Peptides

Sterling’s 25+ years of experience in peptide manufacturing and its state of the art facilities, enables us to deliver the analysis, purification, and manufacturing of novel, long chain peptides.

More about our peptides services

Service.
Passion.
Science.

Great People,
Great Experience

We pride ourselves on our culture and values, which help us to deliver not only an exceptional experience to our customers, but also to our employees. Our people are at the heart of our business, and have made us what we are today.

More about our people and values

The Molecule
Lifecycle

Here’s how we accelerate your product’s path to market by delivering unrivalled support at every stage of the pharmaceutical lifecycle.

A full view of the lifecycle

Discovery

Sterling’s comprehensive analytical and medicinal chemistry expertise, and strong focus on scientific collaboration, enables success in the discovery phase with an eye on containing costs, adhering to deadlines and impact on future phases in the lifecycle.

Preclinical

We pair process development services, including proof of concept, quality by design, and design of experiments, with CMC support for the IND process to establish an efficient, cost-effective, and scalable pathway to market.

Phase One

As our customers prepare for phase I clinical trials, we help them select an appropriate regulatory starting material (RSM), manufacture an appropriate amount of product for clinicaltrials and generate the necessary regulatory data to enhance their chance of success.

Phase Two

After a product moves through phase I, we continue to accelerate the development of materials for clinical trials and generate critical regulatory data, with process optimisation being a key focus for our scientific and engineering teams.

Phase Three

After a product moves through phase I, we continue to accelerate the development of materials for clinical trials and generate critical regulatory data, with process optimisation being a key focus for our scientific and engineering teams.

Launch

After a product moves through phase I, we continue to accelerate the development of materials for clinical trials and generate critical regulatory data, with process optimisation being a key focus for our scientific and engineering teams.